Nanomix, Inc. Appoints New CFO

EMERYVILLE, Calif., June 30, 2014 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on the development of next generation mobile diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced the appointment of Brian Jung as Vice President of Finance and Chief Financial Officer. Mr. Jung brings significant financial and executive experience to Nanomix, having served in CFO and executive roles for several healthcare and life science companies.

"We are very excited to have Brian join the Nanomix team," said David Ludvigson, President and CEO of Nanomix. "As we drive to the commercial launch of our first product, Brian's financial and business background coupled with his experience in our target customer market, will add important depth to our team."

Nanomix is targeting initial commercial launch of its mobile diagnostic platform in 2015 with tests for use by EMS First Responders and Emergency Departments. The Company secured a major strategic corporate relationship and completed a financing round earlier this year.

Mr. Jung's 20 years of financial and healthcare experience includes roles as Chief Business Development Officer at Alameda Hospital and Chief Financial Officer at Cal eConnect as well as management level financial positions with Kaiser Permanente, Blue Shield of California, United Behavioral Health, and McKesson HBOC. Mr. Jung holds an MPH from the Harvard School of Public Health, an MBA from the Johnson School of Management at Cornell University and a Post-Graduate diploma from the London School of Economics.

For more information, visit: http://www.nano.com

Contact:
Joy Bissell
[email protected]
Nanomix, Inc.
5980 Horton St, Suite 600
Emeryville, CA 94608
Phone: 1-510-428-5300

SOURCE Nanomix Inc.

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.